WABCO Holdings Inc. (WBC) reported second quarter EPS of $1.69 Thursday morning, up from $1.43 a year ago. Analysts expected EPS of $1.54. The company also increased its full year EPS forecast to between $6.05 and $6.35, from prior expectations of $5.55 to $6.05.
Vertex Pharmaceuticals Inc. (VRTX) announced positive data from Phase 1 and Phase 2 studies of three different triple combination regimens in people with cystic fibrosis who have one F508del mutation and one minimal function mutation.
Netflix Inc. (NFLX) reported second quarter EPS of $0.15 after the bell Monday, up from $0.09 in the previous year. Analysts expected EPS of $0.16. Revenues rose 32.2% to $2.79 billion from $2.11 billion last year.
Arena Pharmaceutical Inc. (ARNA) announced after the bell Monday that its Phase 2 study of Ralinepag demonstrated a statistically significant absolute change from baseline in pulmonary vascular resistance compared to placebo in patients with pulmonary arterial hypertension.
Constellation Brands Inc. (STZ) reported first quarter comparable EPS of $2.34 Thursday morning. Analysts expected EPS of $1.98. The company also increased its full year 2018 comparable EPS forecast to between $7.90 and $8.10, from prior expectations of $7.70 to $8.00.